Long-Term Results of a Randomized Controlled Trial in Childhood IgA Nephropathy

Koichi Kamei(National Center For Child Health and Development), Norishige Yoshikawa(Takatsuki General Hospital), Mari Saito(National Center For Child Health and Development), Shuichi Ito(Yokohama City University), Hiroshi Hataya(Japanese Society for Dialysis Therapy), Kenji Ishikura(Kitasato University), Masataka Honda(Rikkyo University), Koichi Nakanishi(University of the Ryukyus), Mayumi Sako(National Center For Child Health and Development), Kazumoto Iijima(Kobe Children's Hospital)
Clinical Journal of the American Society of Nephrology
April 14, 2011
10.2215/cjn.08630910
Cited by 98

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135